GlassScriptPhysician profile
Ololade Adekoya
NPI 1144686569
$5,733.32
in general payments reported to CMS, 2019-2025
23 companies · $3,394 in 2025
The $3,394 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.41 · 2022: $222 · 2023: $45.94 · 2024: $2,056 · 2025: $3,394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,495.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,114.05 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $900.93 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $766.11 | 2024-2025 | Caplyta |
| Lundbeck LLC | $511.89 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Axsome Therapeutics, INC. | $431.54 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $385.36 | 2024-2025 | Ingrezza |
| Indivior INC. | $317.75 | 2024-2025 | Sublocade |
| Janssen Pharmaceuticals, INC | $258.41 | 2024-2025 | Spravato |
| Supernus Pharmaceuticals, INC. | $197.52 | 2025 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $183.73 | 2025 | Cobenfy |
| Corium, LLC | $112.93 | 2024-2025 | Azstarys |
| Biogen, INC. | $107.23 | 2025 | Zurzuvae |
| Alexion Pharmaceuticals, INC. | $97.43 | 2022 | |
| Alkermes, INC. | $96.46 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Bausch Health US, LLC | $72.05 | 2025 | Aplenzin |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tms Neurohealth Centers INC. | $43.65 | 2025 | Tms Neurohealth Centers INC. |
| Teva Pharmaceuticals USA, INC. | $28.88 | 2024 | Austedo Xr |
| Neos Therapeutics, LP | $22.14 | 2024 | Adzenys Xr-Odt |
| Tris Pharma INC | $21.62 | 2025 | Dyanavel Xr |
| Sage Therapeutics, LLC | $17.43 | 2025 | Zurzuvae |
| Abbott Laboratories | $17.00 | 2023 | Freestyle Libre 2 |
| Orexo US, INC. | $15.48 | 2024 | Zubsolv |
| Takeda Pharmaceuticals U.S.A., INC. | $13.73 | 2025 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ololade Adekoya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.